Delphine C M Rolland
Overview
Explore the profile of Delphine C M Rolland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
313
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murga-Zamalloa C, Rolland D, Polk A, Wolfe A, Dewar H, Chowdhury P, et al.
Clin Cancer Res
. 2019 Oct;
26(3):690-703.
PMID: 31636099
Purpose: Peripheral T-cell lymphomas are clinically aggressive and usually fatal, as few complete or durable remissions are achieved with currently available therapies. Recent evidence supports a critical role for lymphoma-associated...
2.
Rolland D, Lim M, Elenitoba-Johnson K
Semin Hematol
. 2018 Dec;
56(1):52-57.
PMID: 30573045
Mass spectrometry-based techniques now enable the unbiased identification of proteins in complex mixtures including proteins isolated from cells and tissues. These powerful tools permit near-complete annotation of proteins expressed in...
3.
Awasthi A, Rolland D, Ayello J, van de Ven C, Basrur V, Conlon K, et al.
Oncotarget
. 2018 Jan;
8(69):113895-113909.
PMID: 29371955
We recently demonstrated that obinutuzumab (GA101), a novel glycoengineered type II CD20 Ab compared to rituximab (RTX) mediates significantly enhanced antibody-dependent cell cytotoxicity (ADCC) and increased overall survival in a...
4.
Frattini V, Pagnotta S, Tala , Fan J, Russo M, Lee S, et al.
Nature
. 2018 Jan;
553(7687):222-227.
PMID: 29323298
Chromosomal translocations that generate in-frame oncogenic gene fusions are notable examples of the success of targeted cancer therapies. We have previously described gene fusions of FGFR3-TACC3 (F3-T3) in 3% of...
5.
Rolland D, Basrur V, Jeon Y, McNeil-Schwalm C, Fermin D, Conlon K, et al.
Proc Natl Acad Sci U S A
. 2017 Jun;
114(25):6581-6586.
PMID: 28607076
Identification of biomarkers and therapeutic targets is a critical goal of precision medicine. N-glycoproteins are a particularly attractive class of proteins that constitute potential cancer biomarkers and therapeutic targets for...
6.
Sahasrabuddhe A, Rolland D, Banerjee P
Biomark Cancer
. 2016 Feb;
7(Suppl 2):33-5.
PMID: 26917979
No abstract available.
7.
Kiel M, Sahasrabuddhe A, Rolland D, Velusamy T, Chung F, Schaller M, et al.
Nat Commun
. 2015 Sep;
6:8470.
PMID: 26415585
Sézary syndrome (SS) is an aggressive leukaemia of mature T cells with poor prognosis and limited options for targeted therapies. The comprehensive genetic alterations underlying the pathogenesis of SS are...
8.
Udager A, Rolland D, McHugh J, Betz B, Murga-Zamalloa C, Carey T, et al.
Cancer Res
. 2015 May;
75(13):2600-2606.
PMID: 25931286
Inverted sinonasal papilloma (ISP) is a locally aggressive neoplasm associated with sinonasal squamous cell carcinoma (SNSCC) in 10% to 25% of cases. To date, no recurrent mutations have been identified...